The Point About Primary Immune Thrombocytopenia (Asynchronous)

The Point About Primary Immune Thrombocytopenia (Asynchronous) is organized by Dynamicom Education Srl.

Registration starts : 15-07-2021
End of registration: 14-07-2022

Overview:
Primary Immune Thrombocytopenia (ITP) is a rare form of autoimmune disease characterized by a deficiency of blood platelets (thrombocytopenia or thrombocytopenia) in the absence of other associated diseases. The extent of the bleeding symptoms varies considerably from person to person: it can go from mucocutaneous bleeding with purpura to severe gastrointestinal or cerebral bleeding, more rare but potentially fatal. In about one third of cases, the disease develops asymptomatically.
Despite significant advances in pathophysiological knowledge, the diagnosis of primary ITP (Primary Immune Thrombocytopenia) remains a diagnosis of exclusion. In cases not responsive to first-line therapies and before proceeding to more demanding therapies such as splenectomy, TPO-RA (Thrombopoietin Receptor Agonists) or immunosuppressive agents, it is advisable to re-evaluate the diagnosis, also considering the opportunity of bone marrow examination, unless previously performed, particularly in elderly patients. The treatment of ITP (Primary Immune Thrombocytopenia), not being free from toxicity, is justified only when there is a real risk of bleeding. The efficacy and relative safety of TPO-RAs (Thrombopoietin Receptor Agonists) are well established. The placement of these agents within a sequential therapeutic algorithm does not find unanimous consensus, even if the use of TPO-RA (Thrombopoietin Receptor Agonists) before rather than after splenectomy is progressively affirming itself. In particular, their use during the persistent phase of ITP (Primary Immune Thrombocytopenia) appears reasonable and may represent the preferable option. As highlighted, considerable limitations remain in traditional therapies, especially for their long-term toxicity, such as to limit their use in a systematic manner and for prolonged periods. New therapeutic possibilities are being tested by various companies, looking for drugs with specific mechanisms of action, based on new pathophysiological knowledge (eg.
The aim of the course is precisely to take stock of the management of the patient affected by ITP (Primary Immune Thrombocytopenia) in the light of current knowledge

Educational objective:
• 3 - Clinical documentation. Clinical-assistance diagnostic and rehabilitation paths, assistance profiles - care profiles